Vator Securities advises Medfield Diagnostics on 33 MSEK Rights Issue
Medfield is a medical technology company that has developed the product MD100 Strokefinder, a device powered by AI and microwave technology that can distinguish stroke patients from healthy individuals and differentiate between strokes caused by a clot and those caused by a hemorrhage.
By routing the patient directly to a stroke or trauma center, qualified treatment can be started much faster, leading to time savings, faster care, better outcomes, and lower healthcare costs. The company generates revenue through the sale of the MD100 system, software upgrades, service and maintenance, and disposable materials.
Read More
Vator Securities advises Moberg Pharma on 100 MSEK Rights Issue
Moberg Pharma AB (publ) is a Swedish pharmaceutical company with a focus on the commercialization of proprietary medicines based on proven substances. The company’s main asset is MOB-015 – a new topical treatment for nail fungus. Phase 3 clinical studies of more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis.
Moberg Pharma has agreements with commercial partners on site in Europe and Canada, among others. MOB-015 was recommended for market approval in the EU June 2023.
Read More
Vator Securities advises ZignSec on 26 MSEK Rights Issue
ZignSec is a RegTech company, providing an integrated end-to-end KYC, KYB compliance platform, facilitating seamless customer onboarding and monitoring, so clients can confidently expand operations internationally while remaining compliant.
The platform is constantly evolving by addition of best-of-breed services and tools to enhance the customer experience. ZignSec has hundreds of customers spread across a range of industries where identification is essential, with the greatest concentration in financial services and other regulated activities.
Read More
Vator Securities advises AAC Clyde Space on 74 MSEK Rights Issue
AAC Clyde Space is a leading global small satellite specialist with the goal of becoming a world leader in providing high-quality and timely space data (Space Data as a Service), which can be applied to meet global challenges and improve life on Earth. To date, ~30 satellites have been designed, manufactured, and launched.
AAC Clyde Space specializes in small satellite technologies and services that enable businesses, governments, and educational organizations to access high-quality, timely data from space.
Read More
Vator Securities advises ChromoGenics on 30 MSEK Rights Issue
ChromoGenics is a proptech company producing smart dynamic glass that improves indoor environments and well-being whilst lowering the buildings’ energy consumption, operating expenses and climate impact. The company’s product ConverLight® Dynamic is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic film.
The result is a dynamic film that can be laminated between glass layers, which provides buildings with exceptional solar protection and lowered environmental impact from production,transport and use. The dynamic film is easy to transport and can be applied by local partners in the glass industry, which means it is possible to avoid long-distance and polluting shipping of bulky glass.
Read More
Vator Securities acts as Sole Global Coordinator and Sole Bookrunner in ExpreS2ion Biotechnologies 102 MSEK Rights Issue
ExpreS2ion Biotechnologies is a biotechnology company that develops vaccines based on complex proteins targeting infectious diseases and cancer. The company develops a pipeline of preventive and therapeutic vaccine products while generating revenue by outlicensing the company’s ExpreS2 platform.
The lead candidate targeting COVID-19 is outlicensed to Bavarian Nordic, with positive phase II data announced in February 2022 and phase III initiated during September 2022. ExpreS2ion has a strong pipeline with multiple candidates in pre-clinical phase.
Read More
Vator Securities acted as Sole Global Coordinator and Sole Bookrunner in Immunovia 202 MSEK Rights Issue
Immunovia is a diagnostics company with the vision to revolutionize blood-based diagnostics and increase the survival rate for patients with cancer. Immunovia has launched the first blood test in the world designed for the early detection of pancreatic cancer, a serious form of cancer with a low survival rate. The low survival rate is explained by the fact that pancreatic cancer is usually detected at a late stage when the tumor has metastasized.
Immunovia has developed IMMray® PanCan-d, which is the first blood-based test specifically developed for the early diagnosis of pancreatic ductal adenocarcinoma (PDAC). Since 2016, Immunovia has conducted several large-scale studies targeting the main pancreatic cancer risk groups. Altogether, the studies have been conducted at around 30 hospitals in the USA and Europe and included several thousand patients. Based on the studies conducted, Immunovia’s assessment is that IMMray® PanCan-d has unmatched clinical performance for the early detection of pancreatic cancer.
Read More
Vator Securities advises SciBase on 80 MSEK Rights Issue
SciBase Holding is a MedTech company that develops point-of-care instruments for non-invasive detection of atopic dermatitis (eczema), skin cancer and other skin diseases. The products are based on the company’s technology platform that combines artificial intelligence (AI) with Electrical Impedance Spectroscopy (EIS), a technology based on more than 20 years of research at the Karolinska Institute.
SciBase’s products include Nevisense and Nevisense Go and currently the platform is addressing detection of atopic dermatitis (eczema), melanoma and non-melanoma skin cancer. Nevisense is the only product that is approved by the Food and Drug Administration (FDA) for detection of melanoma and is the only instrument in Europe with a Medical Device Regulation (MDR) approval for detection of skin cancer.
Read More